(Q42246989)

English

Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.

scientific article published on 20 September 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age. (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

influenza vaccine

1 reference

based on heuristic

inferred from title

Geoffrey J Gorse

1

object named as

Geoffrey J Gorse

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

author name string

Ann R Falsey

2

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Carol M Johnson

3

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Dennis Morrison

4

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

David L Fried

5

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

John E Ervin

6

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

David P Greenberg

7

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Ayca Ozol-Godfrey

8

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Victoria Landolfi

9

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Peter H Tsang

10

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

language of work or name

0 references

publication date

20 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

50

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

6034-6040

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.012

7 January 2021

The annual impact of seasonal influenza in the US: Measuring disease burden and costs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.012

7 January 2021

Modeling the cost of influenza: the impact of missing costs of unreported complications and sick leave

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.012

7 January 2021

Fluzone(®) Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.012

7 January 2021

Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.012

7 January 2021

Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.09.012

7 January 2021

Identifiers

10.1016/J.VACCINE.2013.09.012

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42246989&oldid=1801579201"